Speakers Page

N.	Title	Action
1	Document Sample	Click to Open
2	Document Sample	Click to Open
3	Document Sample	Click to Open
4	Video Sample	Click to Open
5	Video Sample	Click to Open
6	Video Sample	Click to Open

Session Number	Presenter	Session	Presentation title	Access
OS-1	Daniel Simões (mod.), Jürgen Rockstroh (mod.) Ricardo Baptista Leite, Dorthe Raben	Opening Session	Part 1 of the live transmission (OS)	View Session
OS-2	António Lacerda Sales	Opening Session	Welcome message from the Portuguese Minister of Health	View Session
OS-3	John Ryan	Opening Session	Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the future	View Session
OS-4	Andrea Ammon	Opening Session	Post-2020/Covid-19 and progress towards the SDG targets: Where are we ?	View Session
OS-5	Hans Kluge	Opening Session	‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19	View Session
OS-6	Daniel Simões (mod.), Jürgen Rockstroh (mod.), Rui Portugal; Panel discussion feat. all speakers of the OS	Opening Session	Part 2 of the live transmission (OS)	View Session
PS1-1	C. Lane	Plenary Session 1	Perspectives from the US National Institute of Allergy and Infectious Diseases of the National Institutes of Health	View Session
PS1-2	A. Sullivan	Plenary Session 1	Impact of the COVID-19 pandemic on linkage to and retention in care for HIV, hepatitis B and C and sexually transmitted infections in the WHO European Region	View Session
PS1-3	C. Kantwerk	Plenary Session 1	s.a.m Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyond	View Session
PS1-4	V. Stanilevskiy	Plenary Session 1	Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, Russia	View Session
PS1-5	B. Collins	Plenary Session 1	European testing week: adaptation of testing services during the COVID-19 pandemic	View Session
AS1-1	L. Cosmaro	Abstract Driven Session 1	RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI	View Session
AS1-2	J. Taylor	Abstract Driven Session 1	An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policy	View Session
AS1-3	C. Agustí	Abstract Driven Session 1	Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trial	View Session
AS1-4	A. Basu	Abstract Driven Session 1	Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdown	View Session
PS2-1	C. Estcourt	Plenary Session 2	“Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in Scotland	View Session
PS2-2	P. Hoffmann	Plenary Session 2	Combination disease prevention in prisons: a comprehensive programme in Luxembourg	View Session
PS2-3	G. de Vries	Plenary Session 2	Good example of TB combination prevention in Netherlands	View Session
PS2-4	E. Smout	Plenary Session 2	The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in England	View Session
PS3-1	Raimonda Matulionytė	Plenary Session 3	Experiences in innovative testing approaches for HIV, hepatitis, STIs and TB	View Session
CS	Michel Kazatchkine (Moderator) Jürgen Rockstroh (Moderator), Cary James, Andrew Winter, Jens Lundgren, Nicole Seguy, Yazdan Yazdanpanah, Nikoloz Chkhartishvili, Paul Sommerfeld, Nikos Dedes, Ricardo Baptista L	Closing Session	Integrating disease areas and settings	View Session
PS3-2	Maka Danelia	Plenary Session 3	Integrated screening for TB, HIV and HCV at the primary healthcare level	View Session
PS3-3	M. Gogishvili	Plenary Session 3	Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019	View Session
PS3-4	Robert Hejzak	Plenary Session 3	Implementing self-test programmes during COVID-19	View Session
AS2-1	R. Teodorescu	Abstract Driven Session 2	Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategy	View Session
AS2-2	S. Shirley-Beavan	Abstract Driven Session 2	Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overview	View Session
AS2-3	S. Mazzilli	Abstract Driven Session 2	Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy	View Session
AS2-4	E. Emanuel	Abstract Driven Session 2	Blood-borne virus testing in people who inject drugs with a history of sex work	View Session
AS2-5	R. Rigoni	Abstract Driven Session 2	HCV care for PWID in Europe - results from a civil society-led monitoring	View Session
PS4-1	Thomas Seyler	Plenary Session 4	Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: a European perspective	View Session
PS4-2	Otilia Mardh	Plenary Session 4	New evidence on testing and linkage to care for PWIDs	View Session
PS4-3	Marios Atzemis	Plenary Session 4	Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic	View Session
PS4-4	Fadi Meroueh	Plenary Session 4	What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs?	View Session

Epidemiologist at the Centre for Epidemiological Studies of Sexually Transmitted Disease and AIDS in Catalonia (CEEISCAT) (Badalona, Spain), PhD in Experimental and Health Sciences, Master in Experimental Biology, with 14 years of research experience in HIV and STIs diagnosis. She leads the research line on new strategies to promote early diagnosis of HIV and STIs of CEEISCAT. She is the principal investigator (PI) of the TESTATE HIV Project and TESTATE COVID. She also coordinates the TESTATE C Plus project and the study “Efficacy of a training intervention and the implementation of an electronic alert in computerized medical records to improve early diagnosis of HIV and other STIs in Primary Care: A randomized clinical trial”. She was de co-Project manager of the HIV-COBATEST and Euro HIV EDAT projects both co funded by CHAFEA.

6 May 2021 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage:
AS1/03 Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster randomized controlled trial
Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling: PO3/05 TESTATE C Plus: an online self-sampling intervention for hepatitis C in gay, bisexual and other men who have sex with men and trans women in Catalonia (Spain).
PO3/06 High acceptability and effectiveness of an online self-sampling intervention for HIV in gay, bisexual and other men who have sex with men and trans women in Spain (TESTATE VIH)

Olga Anagnostou is a Medical Doctor, specialized in Internal Medicine with a master’s degree in Public Health. She works as a physician for two decades in the substitution units of the Greek Organization against Drugs (OKANA). Her clinical work is complemented by a particular interest in Public Health.

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/03 Hepatitis C cascade of care (CoC) for people who use drugs (PWUD) under opiate substitution treatment (OST) in Greece

PhD of Sociology, CEO of Foundation for Social Education, Coordinator of programs, sexual educator and trainer of workshops. Coordinator of two CBVCTs in Warsaw, Mobile Testing Unite, and HIV selftest Programme, sexual educator, researcher, member of IAS, EACS (WAVE and YING), the Polish AIDS Scientific Society, member of Polish HIV guidelines experts group and member of European AIDS Treatment Group (EATG), editorial reviewer member in EUPATI, author of publications

Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling: PO3/02 Self HIV testing in Poland implementation during COVID-19

Marios Atzemis was born in Athens on 6 December 1974. He graduated
from Athens College in 1992 and from the American College of Greece in 2000 with a
Bachelor of Arts (Sociology)2014,Marios has been working for the Greek Association of
People Who Live With HIV ”Positive Voice” in harm reduction projects for people who
use drugs and also in the field of advocacy taking part in numerous committees.From
2016, he is an ordinary member of the European AIDS Treatment Group and in the
Board of Drug Policy Network of South East Europe . He has attended and has participated in numerous sessions, meetings, workshops and conferences as a guest speaker both in Greece and abroad.
He represents EATG in the Civil Society Forum on Drugs (consulting body of the EU) and
in the Committee on Narcotic Drugs of United Nations in Vienna. He is also a board
member of AIDS Action Europe.

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): PS4/03 Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic

Bachelor degree in Psychology.
Harm reduction worker at GAT- InMouraria since 2016 and also Coordination Assistant in the same service since 2019.
Previous experiences in community projects, in Portugal and Spain, with vulnerable populations.
Feminist and LGBTI+ activist.

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/04 Decentralized HCV consultation: an HCV micro-elimination project in the community

Anamika Basu is a public health specialist trainee in London, UK, currently working at SH:24, an online sexual health service. Previous work placements as part of training have included working under Public Health England, in the South London Health Protection Team and the London Coronavirus Response Cell, with a focus on supporting outbreak management in schools and universities; at the London School of Hygiene and Tropical Medicine looking at the outcomes of NHS policy, and is where she also did her MSc in Public Health; and 12 months working in Croydon Local Authority as part of the local public health team. Prior to that she was an E-Learning Teaching Fellow at Barts and The London School of Medicine and Dentistry, part of Queen Mary University of London, and worked as a junior doctor for three years across North East London. Specialist interests include health communication and health promotion, commercial determinants of health and digital health.

6 May 2021 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage:
AS1/04 Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdown

I am an infectious diseases resident doctor at the University Hospital for Infectious Diseases in Zagreb, Croatia, currently enrolled in a second year of residency. My particular interest in infectious diseases field is HIV/AIDS and I am involved in HIV research activities. Additionally, I work at CheckPoint Zagreb – community based centre for education and voluntary, confidential and free rapid testing for HIV, HCV and syphilis. I had clinical experience at infectious diseases & HIV at the Froedtert Hospital, Milwaukee, USA in 2016, Hospital for Tropical Diseases, London in 2017 and Modena HIV Metabolic Clinic of the University of Modena and Reggio Emilia, Italy in 2018 as a student and junior medical doctor. I participated in several international conferences regarding infectious diseases/HIV.

Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling: PO3/03 Premlinary results of a pilot project on HIV self-testing among men who have sex with men in the City of Zagreb, Croatia, 2020/2021

Jordi Casabona is a medical epidemiologist trained in Public Health in US. He has been working on the field of HIV/STIs since 1987 both at the local and international level. Among other he has worked at the Global Program on AIDS (GPA/WHO) and he has been the Director of the Program on HIV Prevention Control in Catalonia. He has been consulting for WHO, UNAIDS and the Global Fund, the Co-President of the XIV International AIDS Conference (Barcelona, 2002) and leader of different projects funded by the European Commission.Currently he is the Scientific Director of the Center for Epidemiological Studies on STIs, HIV and AIDS (CEEISCAT), the President of the Fundació SIDA i Societat and professor at the Universitat Autònoma de Barcelona (UAB) and at the Universitat Oberta de Catalunya (UOC). He is member of the Executive Committee of EUROTEST, of the COBATEST Network and of the RIGHT + Network. He is author of more that 220 scientific publications in his field.

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

7 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies: Moderator

I’m working at HIV/STIs/hepatitis area and representing of ALLIANCE.GLOBAL, NGO almost 18 years. From 2015 to the present day, I’m the Head of Advocacy & External Communication Department. I`m a community advocate that protects the interests of MSM/LGBTI+ community in Ukraine, I`m a member of the Country Coordination Mechanism (CCM). I also have extensive successful experience in project management related to HIV prevention among MSM, launching innovative projects such as pre-exposure HIV prophylaxis in Ukraine, vaccination against HBV, budget advocacy, as well as strengthening the leadership and organizational capacity of MSM and other key HIV groups. I have also worked to improve access to treatment and prevention programs for viral hepatitis for MSM. Since 2009, I have been conducting bio-behavioral research among MSM in Kyiv, In 2017-18, I successfully organized and conducted the first pilot study in Ukraine among MSM who use drugs and practice Chemsex.

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned: PO1/06 Use of mobile applications and social networks for HIV testing among MSM and PrEP obtaining at COVID-19 conditions, in Ukraine

Primary School Teacher of Mathematics and Nature Sciences;
Master’s degree in Didactics of Sciences;
PhD in Education;
Post-Graduation in Supervision and Orientation of Professional Practice;
Post-Graduation in Social Service Intervention in Health;
Professional Training Course of Trainers Training for Specialization in Gender Equality;
Course CRISH – Co-create Innovative Solutions for Health;
Educational Coaching;
Master Coaching Skills – Live and Health Coach
Trainer Accredited by the Scientific-Pedagogic Council of Continuous Training of the University of Minho CCPFC/RFO – 30442/11;
Founding member of the Group of Studies and Research in Sexuality, Sexual Education and ICT;
Advisor to the Board of Directors of the Portuguese Foundation “A Comunidade Contra a SIDA”, an NGO, with a remarkable work in the area of prevention, monitoring and guidance to HIV/AIDS issues (since 2016).
President of the Board of the Maiorca Delegation of the Portuguese Red Cross

Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO5/05 Contributions of (+) Screening = (+) Life Project in the access of the Trans and Sex Worker population to early detection and screening of STIs

Sara Croxford is a Principal Scientist for the Drug and Infections team at Public Health England. She was recently awarded her PhD in Epidemiology and Public Health from University College London.

Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs: PO2/01 Changes to the provision of services for people who inject drugs in England, Wales and Northern Ireland during the COVID-19 pandemic

MD, PhD, MSc in Health Systems Management. Currently works as Global Fund Tuberculosis Program Manager, National Center for Disease Control and Public Health, Georgia. She has extensive experience of participation in multilateral efforts related to communicable and non-communicable diseases engaging primary healthcare providers.

7 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies: PS3/02 Integrated screening for TB, HIV and HCV at the primary healthcare level

Dr Gerard de Vries is the National Coordinator of TB Control in the Netherlands (RIVM). He is also the RIVM-project lead of the ECDC project ‘Country support for TB elimination in Europe’ (2019-2023) and responsible for TB collaborative activities with the national TB programme in Suriname (2019-2024).

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: PS2/03 TB an HBV/HCV/HIV-combined preventive activities in the Netherlands

I completed my Master of Public Health from Imperial College London in 2020 and I am now working as a blood-borne virus prevention and surveillance scientist at Public Health England.

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: AS2/04 Blood-borne virus testing in people who inject drugs with a history of sex work

Claudia Estcourt is Professor of Sexual Health & HIV at Glasgow Caledonian University, and a consultant physician. Her research addresses: 1). HIV PrEP public health programmes, service development, evaluation and monitoring; 2). Self-managed, digital healthcare; 3). Interventions to prevent STI & HIV transmission. She leads evaluation of PrEP in Scotland.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: Moderator

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Dra. Laura Fernàndez-López, Bsc PhD, works as an epidemiologist at the Center for Epidemiological Studies on STIs, HIV and AIDS in Catalonia (CEEISCAT). She coordinates the monitoring of HIV testing in Catalonia and has several national and international articles in this field. She has extensive experience in European projects, acting as co-project manager of the HIV-COBATEST and EURO-HIV-EDAT projects. She is the coordinator of the COBATEST network, a European network of community-based HIV testing services.

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned: PO1/01 Impact of the COVID-19 pandemic on community-based testing for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region

Cinta Folch, MPH, PhD, is a senior epidemiologist at the Center for Epidemiological Studies on STIs, HIV and AIDS of Catalonia, Spain (CEEISCAT) since 2000. She has been coordinating bio-behavioral HIV/ STI surveillance studies among vulnerable populations since 2002, has published several national and international articles in this field, and collaborated in several European Union financed projects.

Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/myncbi/1bMFrJa4dQyQmp/bibliography/public/

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/01 Socio-demographic inequalities in HIV testing patterns among MSM in Spain

Dr.Megi Gogishvili is Field Coordinator for COBATEST project at Germans Trias i Pujol Health Sciences Research Institute Foundation, Centre for Epidemiological Studies of Sexually Transmitted Disease and AIDS in Catalonia (CEEISCAT).
Her prior work experience ranges from local private and public companies to international organizations such as UNICEF, World Vision International and Blacksmith Institute (Pure Earth). Dr.Gogishvili’s work experience also includes teaching positions in the field of public health planning and management at the City University of New York and International University of Valencia.
Dr.Gogishvili earned her doctorate degree in Public Health with a specialization in health policies and management from City University of New York. She also earned a Master’s Degree in Social Work and Project Management from Columbia University in the city of New York. As a social worker and doctor in Public Health, Dr.Gogishvili is dedicated to addressing health inequities.

7 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies: PS3/03 Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 2017-2019
Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings: PO5/01 Community-based voluntary counseling and testing for HIV, sífilis and HCV in Europe: COBATEST Network 2019

Dr. Ilias Gountas is a Postdoctoral Researcher at the Faculty of Social and Political Sciences of the University of Peloponnese. He has significant research experience in the field of mathematical modeling, mainly those of Hepatitis C and HIV. He trained in infectious disease modeling at the Center for Disease Analysis in Colorado, USA. His Ph.D. dissertation informed the Greek HCV elimination Action Plan of the Ministry of Health.

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/06 Could the 2010 HIV outbreak in Athens, Greece be prevented? A mathematical modelling study

For the past 8 years Robert Hejzak has been serving as the Board Chair of the Czech national patient organization for persons living with HIV (Czech AIDS Help Association). A patient advocate, Robert has been looking out for the best interests of HIV patients and campaigning for new HIV prevention tools, promoting destigmatization measures and access to care for all patients.

Robert is a patient representative on the Czech National HIV Committee, a member of Euroepan AIDS Treatment Group (EATG), a member the Czech National Patient Council and a founding member of the Czech National Association of Patient Organizations.

7 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies: PS3/05 Implementing self-test programmes during COVID-19

Born in 1979, social scientist B. A., project coordinator Checkpoints at Deutsche Aidshilfe, since 2016 at Deutsche Aidshilfe.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: PS1/03 s.a.m Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the Covid-19 Pandemic and beyond

Professor Michel Kazatchkine has over 35 years of experience in global health as a leading physician, researcher, administrator, advocate, policymaker, and diplomat. He is an Emeritus Professor of Immunology at René Descartes University in Paris and has authored or co-authored over 500 scientific publications. Professor Kazatchkine has played key roles in various organizations, serving as Director of the National Agency for Research on AIDS in France, French ambassador on HIV/AIDS and communicable diseases, Executive Director of the Global Fund to fight AIDS, Tuberculosis and Malaria, and UN Secretary-General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia (EECA).
Since 2018, he is the Special Advisor to the Joint UN Programme on HIV/AIDS (UNAIDS) for EECA. He is also Senior Fellow with the Global Health Centre of the Graduate Institute in Geneva, a member of The Independent Panel for Pandemic Preparedness and Response, and the Global Commission on Drug Policy.

7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Moderator

Dr Hans Henri P. Kluge is the WHO Regional Director for Europe. His term began on 1 February 2020, following his nomination by the WHO Regional Committee for Europe and appointment by the WHO Executive Board.

Throughout his career, beginning as a family doctor in Belgium, along a journey to Somalia, Liberia, the prisons in Siberia, former Soviet Union countries, Myanmar and the Democratic People’s Republic of Korea, and most recently leading the Division of Health Systems and Public Health at WHO/Europe for a decade, Dr Kluge has always been committed to achieving better health for all with a focus on the vulnerable.

As Regional Director, Dr Kluge’s vision for the WHO European Region is “United action for better health”, working in partnership to achieve universal health coverage, address health emergencies and promote healthier populations.

Dr Kluge is from Belgium. He is married and has two daughters

5 May 2021 Opening Session: OS/05 ‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19

Professor Jack Lambert is a Consultant in Infectious diseases at the Mater hospital and Rotunda Maternity hospital in Dublin since 2005, he also has an adjunct academic teaching appointment at the UCD School of Medicine. Professor Lambert has over 25 years experience, in Infectious Diseases covering HIV, Hepatitis C, and other disease areas. He trained in the USA, UK, and worked for 6 years in Baltimore at the Johns Hopkins Institutes and the University of Maryland Institute of Human Virology, where he developed his skills in vaccinology, HIV, and Lyme and Co Infections. He has also been involved in the Sexual Health Strategy group in Ireland and teaching GP’s throughout the country on the subject of STD’S.

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist
Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs: PO2/04 Using peer support to facilitate hepatitis C treatment during the COVID-19 pandemic

H. Clifford Lane, M.D., is Clinical Director and Deputy Director for Clinical Research and Special Projects for the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH). He serves as co-chair of the US Treatment Guidelines for HIV and the NIH Treatment Guidelines for COVID-19.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: PS1/01 Keynote Address: Overview of the impact of COVID-19 on progress toward the SDG targets

Prof Lazarus is an expert on health systems and infectious diseases known for having developed the “Fourth 90” in HIV/AIDS and the HCV micro-elimination approach. He serves as head of the health systems team at the Barcelona Institute for Global Health (ISGlobal) and an Associate Professor at the Faculty of Medicine, University of Barcelona.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: Moderator

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist
Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs: PO2/03 The impact of the COVID-19 pandemic on harm reduction services in a prison and addiction centres in the Balearic Islands, Spain: preliminary results from a novel hepatitis C elimination programme
Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/04 Quality of life in people living with HIV in Romania and Spain
Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/07 Eliminating hepatitis C on the Balearic Islands by linking patients who use drugs from addiction service centers, a local NGO, a prison and a mobile methadone bus to HCV care

Mihai Lixandru is an HIV activist and trainer with extensive experience at national and international level. Currently, Mihai works as a project manager within ARAS – Romanian Association Against-AIDS and is the founder and coordinator of ARAS Checkpoints, the only testing centers for men who have sex with men and trans women in Romania. He represents ARAS in national and international working groups, steering committees, advisory boards and coalitions. He represented Romania between 2015 and 2017 at the Civil Society Forum of the European Commission and is currently a member of the International AIDS Society, Cobatest Network and EATG.

Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling: PO3/04 Get an HIV test at home! Increasing access to testing, in the pandemic context, by implementing a pilot program of home-based HIV testing in Romania

I am medical epidemiologist, working for the European Centre for Diseases Prevention and Control since 2011. I have been involved in activities such as scientific advice, risk assessment, epidemic intelligence and response, with a focus on HIV, STI and hepatitis. Since 2018, I have coordinated from ECDC side the update of the joint ECDC &EMCDDA guidance for prevention of infections among PWID (2011).

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): PS4/02 New evidence on testing and linkage to care for PWIDs

My name is Valentina Mascia and I’ve been working with Lila Cagliari since 2016. I started as a volunteer and then joined as well the national staff at Lila Onlus by translating official papers from International Agencies such as UNAIDS and ECDC. I take part in the testing service staff as counsellor and regularly attend national training sessions about the activities of our NGO and the themes around HIV.

Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO5/02 Rapid Hiv test in Sardinia, a lookback at first 5 years of Lila Cagliari testing service

Raimonda Matulionyte, MD, PhD, is a professor in Vilnius University, Department of Infectious Diseases and Dermatovenerology, and a consultant physician in Vilnius University Hospital. She is a steering committee member of EuroSIDA, a member of Lithuanian Infectious Diseases Society board and a co-author of Lithuanian HIV diagnostics and treatment guidelines.

7 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies: PS3/01 Experience in innovative approach to testing for HIV, hepatitis and STIs

Graduate in Molecular Biotechnology at the University of Pisa, Sara Mazzilli received her Master degree in Global Health in 2019 from the ISGlobal (Barcellona Institute for Global Health).
Currently she is enrolled in a PhD program in Data Science at the Scuola Normale Superiore (Pisa, Italy). Her PhD thesis focus on the COVID-19 impact on vulnerable populations.

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: AS2/03 Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy

Neuropsychologist, working in harm reduction field since 2015. Currently coordinating a Housing First program for people who use drugs and experience chronic homelessness, a point-of-care HCV screening and treatment combined with outreach work, and a community-based research group in CRESCER, a NGO in Lisbon, Portugal. In the past, has worked in a mobile low-threshold methadone program.

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/01 Point-of-care screening combined with nursing and peer-based outreach work to enhance testing and treatment for hepatitis C among people who use drugs, people who experience homelessness, and migrants: the REACH U Study

He is the Head of the Czech National Monitoring Centre for Drugs and drug Addiction at the Office of the Government, which is the member of the Reitox network coordinated by EMCDDA. He is responsible for the national information system in addictions. He is the main author and editor of the Annual reports on the drug situation in the Czech Republic as well as Annual reports on gambling in the Czech Republic.His main interests are drug monitoring, evidence-based drug policy, problematic patterns of drug use and their prevalence, drug-related infectious diseases and other drug-related health consequences, harm-reduction interventions.
He is MD, specialised in epidemiology, has PhD in Preventive Medicine. Since 2018, he has been nominated Associate Professor at the Department of Addictology, First Faculty of Medicine, Charles University, Prague.

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): Moderator

As the social and behavioural researcher at Adam’s Love Global Foundation for MSM and Transgender Health (ALGO) and manager of Adam’s Love (www.adamslove.org) and TemanTeman.org leading technology-based HIV outreach interventions in Thailand, Taiwan, Indonesia, Malaysia and South Korea, I have contributed to successful communications technology in engaging hard to reach and closeted men who have sex with men (MSM) and transgender women (TGW) into early HIV testing and treatment in Southeast and East Asia since 2010 and demonstration of the potential for utilizing ‘Online-to-Offline’ models. Both Adam’s Love and TemanTeman.org have attracted national and regional recognition as a trusted resource on HIV and referral to HIV testing, accessing HIV prevention tools and treatment cascade.

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned: PO1/05 Going cashless in a cash-constrained crisis: Implementation of a COVID-19 emergency response program for optimising engagement in HIV care among Thai men who have sex with men and transgender women

PhD student in health psychology, my thesis focuses on coping strategies of HIV in French Guiana. I am also interested in the community-based approach in the field of HIV and chronic diseases.

Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO5/04 Promoting autonomy and self-care of people living with HIV and/or hepatitis through a community-based approach: the example of the Takari project in French Guiana

PHD in Biology from the University of Seville with a Máster in physiology Neuroscience. Manuel is expert in the management of people living with HIV for the UNED University. Nowadays, Manuel is a sexual health educator in Adhara Sevilla Chekpoint and teacher in the University of Antonio de Nebrija (Madrid). He works in different fields in Adhara for example performing STI and HIV tests and giving different training about sexual health. In the University he teaches subjects in phycology degree and two different Masters in the department of education.

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned: PO1/04 Strengthening community responses on prevention and care for PLHIV and key populations during the COVID-19 emergency crisis

Rafaela is a researcher and a consultant on drug policies. At Correlation- European Harm Reduction Network, she co-leads a Civil Society Monitoring of Harm Reduction in Europe, and works on projects related to stimulant drugs, synthetic opioids and quality standards for drug demand reduction. Rafaela holds a PhD in Development Studies from Erasmus University of Rotterdam.

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: AS2/05 HCV care for PWID in Europe – results from a civil society-led monitoring

I am an Internal Medicine specialist at the Vall d’Hebron Hospital (Barcelona), principal investigator of clinical trials and independent research projects, mainly on viral hepatitis. I achieved my PhD at the UAB, where I am an Assistant Professor. I am a member of CIBERehd and the Scientific Committee of AEEH.

Jürgen Rockstroh, MD, is Professor of Medicine and Head of the HIV Outpatient Clinic,University of Bonn, Germany. His department treats the world’s largest cohort of HIV-infected hemophiliacs. He is also involved in HIV research & has more recently started working on the impact of COVID-19 on HIV-coinfection. Investigator in multiple clinical trials. From 2007-2011German AIDS Society president. Since 2009 executive committee member of the European AIDS Clinical Society (EACS) & from 2011-2020 governing council member of the International AIDS Society. 2011-2017 chair of the National German AIDS Advisory Panel & the EACS coinfection guidelines 2008-2017.From 2015 HIV in Europe chair (now EuroTEST). 2019-2020 EACS president. The German Society for Infectious Diseases awarded Dr Rockstroh and his co-authors the prize in clinical infectious diseases in 2002 & the national AIDS research prize in 2005. Author or co-author of over 700 publications in peer-reviewed journals & 100 book chapters

5 May 2021 Opening Session: HepHIV2021 Lisbon & Virtual Conference Co-chair

7 May 2021 Closing Session: Integrating disease areas and settings: HepHIV2021 Lisbon & Virtual Conference Co-chair

Clinical Psychologist/ Researcher
Masters in Clinical Psychology (2008) and Masters in Health Psychology (2014). Since 2009, experience in health processes and outcomes; chronic disease management; quality of life; health literacy; HIV, viral hepatitis, and STIs; in community-based settings.
Development and management of national and international projects; analysis of internal monitoring indicators for multidisciplinary services; author and speaker at national and international conferences.
Full member of the Portuguese Psychologists Association.

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned: PO1/02 Screening, diagnosis and treatment of HCV/HIV during the COVID 19 pandemic: lessons from a Mobile Outreach Program in Lisbon, Portugal

John F. Ryan is Director of the Commission Public Health directorate since September 2016. Previously, in the same department, he was the Head of Unit responsible for a number of public health policy areas (cancer, drugs, promotion, monitoring, infectious diseases). He was a Commission representative on the Board of the EU Lisbon Drugs Agency,and is currently the Commission representative on the Board of the European Centre for Disease Prevention and Control. He also had the charge of dealing with tobacco control issues. Current priorities include the development of an EU cancer plan, antimicrobial resistance, vaccination policies, and the negotiation of financial instruments to support health, including research. He has previously worked on the completion of the internal market, and on international trade negotiations. He is also an official of the Irish civil service (on leave). He is a fellow of the UK faculty of public health.

5 May 2021 Opening Session: OS/03 Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the future

Executive Director at Baylor Black Sea Foundation and senior clinical health psychologist, Ana-Maria is passionate about designing the right conditions that enable people with chronic diseases better manage their health outcomes.

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/08 HIV and viral hepatitis transmission knowledge among female health care providers and females in the general population in Constanta Region, Romania

Svetlana Semikova was born in Aktyubinsk, USSR in 1966, she moved to the Leningrad region in 1975. She is happily married, has 2 children, 5 grandchildren and also 4 dogs and 1 cat.

Mrs. Semikova has graduated from the St. Petersburg State Medical University named after I.I. Mechnikov in 1995, department of medical and preventive work, has an additional specialization in epidemiology.

Mrs. Semikova has been working at the Leningrad Region AIDS centre from 2006. She has been appointed as an AIDS centre Deputy head doctor in 2015.

Dr. Semikova has been coordinating rapid testing project between AIDS centre and AIDS Healthcare Foundation from 2013.

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/03 Implementation of HIV rapid testing model in government medical facilities in Leningrad Region, Russia in 2020

Scientific Analyst, Public Health Unit, EMCDDA

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): PS4/01 Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: a European perspective

Sam Shirley-Beavan is a Research Analyst in the Public Health and Social Policy team at Harm Reduction International (HRI). In this role, he conducts original research and analysis into harm reduction trends worldwide, including for the biennial Global State of Harm Reduction report. He holds an MA in Conflict, Governance and International Development from the University of East Anglia, and a BA in Spanish and Politics from the University of Bath.

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: Moderator

Elizabeth Smout is a Specialty Registrar on the Public Health training scheme, based in the South West of England. Prior to joining the training scheme, she was a Field Epidemiology Training Programme Fellow with the Yorkshire & Humber Field Epidemiology Service, with this training undertaken in conjunction with the European Programme for Intervention Epidemiology Training (EPIET). Elizabeth has also worked in Sierra Leone with the London School of Hygiene & Tropical Medicine, coordinating community engagement for Ebola vaccine trials. She has a particular interest in embedding social science into public health and epidemiological responses to infectious diseases.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: PS2/04 The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs) in England

Victor Stanilevskiy serves as a Prevention, Testing and Linkage Coordinator at AIDS Healthcare Foundation, Russia from 2015. As a coordinator, Mr. Stanilevskiy oversees AHF partnerships with 9 NGOs in 8 Russian cities/regions mostly effected by HIV.

Focus of work for AHF and partnership NGOs is providing rapid testing consultations, prevention, and linkage to care to bridging and key at-risk populations. From 2015, AHF testing programs in Russia have tested approximately 600,000 clients with seropositivity of 4,2% and linkage to care of over 82%.

Mr. Stanilevskiy lives in Moscow, Russia, has two children and enjoys reading and creative writing.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: PS1/04 Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, Russia
Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/02 Efficiency of HIV rapid testing and social services for IDU women in Tomsk, Russia

Hannah is a research assistant for Grupo de Ativistas em Tratamentos (GAT) where she supports the evaluation of Portugal’s first Mobile Drug Consumption Room. She is currently pursuing a Masters in Public Policy from Central European University and the Barcelona Institute for International Studies. Previously, she was a Fulbright Scholar in Lisbon where she studied Portuguese drug decriminalization.

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/05 Portugal’s first mobile drug consumption room: client characteristics and linkage to care

Dr. Jorge Valencia was born in Lima (Peru). He achieved his medical doctor degree in 2005 and made a post-graduate in infectious diseases in 2011 at the San Marcos University (Perú). He moved in 2012 to Madrid, Spain and granted a fellowship in viral infections research at the La Princesa Hospital (2012 and 2013). Subsequently, he obtained his Master degree in AIDS at the Universitat Autonoma of Barcelona (Spain) in 2014 and achieved his doctorate grade; PhD at the Alcala de Henares University (Madrid, Spain) in 2018. Currently, he is a medical coordinator of a Harm Reduction mobile unit of the Addictions and mental health Office in Madrid (Spain) attending people who injecting drugs with diseases related to injection drug use. He is involved in many researches regarding to bacterial and viral infections occurring in people who injecting drugs, homeless people, migrants and other vulnerable groups. His principal areas of interest are new models of screening, care and treatment delivery

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/08 Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs (PWUD)

Maria Vasileiou is a clinical nurse and has been working at the Evangelismos General Hospital in Athens. Ιn recent years she has worked as a nurse in the substitution units of the Greek Organization against Drugs (OKANA). Her clinical work is complemented by a particular interest in Public Health.

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs: PO6/10 Impact of opiate substitution treatment (OST) on hepatitis and HIV high risk behaviors

Koenraad Vermey is trained in medicine and social sciences. As senior project officer for Aidsfonds – Soa Aids Nederland, Koenraad develops and evaluates innovative interventions for HIV/STI testing and prevention in the Netherlands.

Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling: PO3/01 Key learnings from an HIV at-home testing campaign for Dutch MSM and trans people during the COVID-19 pandemic

Team Lead, HIV, STI and viral hepatitis, Division of Country Health Programmes, World Health Organization regional office for Europe
Dr Nicole Seguy is a medical doctor with expertise in public health and epidemiology. She has been working for WHO since 2005 in Cambodia, China, India and at the regional office for Europe, on HIV and other communicable diseases.. She was trained in medicine in Paris, and has a Masters degree in Public Health from the London School of Hygiene and Tropical Medicine and a degree in epidemiology from the US CDC. She has also practiced clinical care in France, Africa and Asia. Since April 2019, Dr Seguy is the Team lead for HIV, STI and viral hepatitis at the WHO Regional office for Europe and supports countries of the Region to eliminate HIV and hepatitis as public health problems by 2030. Dr. Seguy has more than 20 years of public health experience in HIV, STI, viral hepatitis and other communicable diseases prevention, treatment and strategic information

5 May 2021 Opening Session: Representing the WHO Regional Office for Europe in the live discussion

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: Moderator

7 May 2021 Closing Session: Integrating disease areas and settings: Panellist

Lella Cosmaro has been working in the HIV field since 1993 in an Italian NGO, LILA – the Italian League for Fighting AIDS – one of the leading national organizations.
Over the years, LILA has become more and more involved in European policies and networks: Lella is Italian member of the EU HIV/AIDS, Hepatitis and Tuberculosis Civil Society Forum, which she co-chaired for the period 2012-2015 an is vice-chair of the WHO Regional Coordinating Committee for Tuberculosis, HIV and viral Hepatitis.
She is a Steering Committee member of the COBATEST network, has been a Steering Committee member of AIDS Action Europe from 2011 thru 2016, is one of the Italian Focal Points for the Correlation European HR Network, has been the civil society expert in a number of WHO missions in the European Region and involved in some of the ECDC advisory groups.
LILA has been/is partner in many European projects and Joint Actions and is deeply involved in Italian projects, advocacy and policy issues.

6 May 2021 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage:
AS1/01 RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: Moderator

Professor Cullen is a Family Physician in Dublin, Ireland and Professor of Urban General Practice at the School of Medicine in University College Dublin. His research focuses on how we can best enhance primary care – and its interface with secondary care, to improve health outcomes for people who experience infectious diseases, mental health and substance use problems. He les the primary care component of ‘Hepcare Europe’ which involved the development and evaluation of an integrated model of care for patients with hepatitis C. With collaborators in Ireland’s Health Services Executive, Ireland East Hospital Group, colleagues in primary and secondary care, service user representatives and international experts, this research has realised in excess of 200 peer reviewed publications. Prof Cullen is Head of Subject (General Practice), Academic Lead for the Primary Care Research Group and Director of Quality Improvement at UCD School of Medicine.
https://people.ucd.ie/walter.cullen

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Teymur Noori works at ECDC as an expert on monitoring an evaluation. He is primarily responsible for monitoring the HIV response in Europe and Central Asia, including monitoring the continuum of HIV care, and supporting efforts to monitor the response to viral hepatitis in the EU/EEA.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: Moderator
6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Luís Mendão concluded his studies in biochemistry in 1983 at the University Pierre et Marie Curie, in Paris.
Luís Mendão is currently Chair of the Board of GAT –Treatment Activist Group, an NGO founded in 2001 and working in prevention, early diagnosis, treatment and care of HIV/AIDS, viral hepatitis and tuberculosis focus on key populations. He is also the founder and on the Board of Directors of the AntiProhibitionist Association (SOMA-APA).
Current co-chair of the Civil Society Forum on HIV/AIDS at the European Commission and he’s Chair of the European AIDS Treatment Group (EATG).
Luís Mendão also integrates to the Steering Committee of the HIVPORTUGAL initiative.
In the last ten years, it has been community consultant of the Regional Office of the World Health Organization Europe (WHO Europe), EMCDDA and ECDC.
Luís Mendão was diagnosed with HIV and HCV in 1996.

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Moderator

Daniel Simões is a Psychologist working in the third sector since 2004. Currently Monitoring and Evaluation manager at Coalition PLUS, he collaborates with GAT (Portugal) since 2011 in both project management and policy/advocacy activities. He is the co-chair of EUROTEST, member of the European Testing Week working group, of the European AIDS Treatment Group and the WHO European Laboratory Initiative core group. Daniel is currently finishing his PhD in Global Public Health at the Institute of Public Health of the University of Porto, in Portugal.

5 May 2021 Opening Session: HepHIV2021 Lisbon & Virtual Conference Co-chair. OS/07 Community perspective on enabling environments for integrated testing and linkage to care across Europe

Eberhard Schatz (1955) studied social work in Germany and worked for drug counselling services in Germany and cross-border projects between Germany and the Netherlands. Since 2005, Mr Schatz is one of the coordinators of the Correlation – European Harm Reduction Network. Between 2012 – 2014 he chaired the Civil Society Forum on Drugs, since 2017 he is one of the chairs of the CSF HIV+. He is involved in different advisory boards at the national and international level and the organization of hepatitis and harm reduction related conferences.

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: Moderator

Ann Sullivan is a Consultant Physician in Sexual Health and HIV Medicine at the Chelsea and Westminster Hospital in London and National co-lead of HIV surveillance at Public Health England. Her research interests include HIV testing and PrEP. She was a co-investigator on the PROUD study and is Chief Investigator on the PrEP Impact trial. Her HIV testing research has involved feasibility, acceptability and cost related research to provide the basis for her current implementation research. She has been involved in a number of European projects: HIDES, OptTEST, INTEGRATE, EUROTEST.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: PS1/02 Impact of the COVID-19 pandemic on linkage to and retention in care for HIV, hepatitis B and C and sexually transmitted infections in the WHO European Region
6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Valérie is a public health epidemiologist and Head of the HIV Team at Public Health England. In close collaboration with researchers, clinicians and civil society, for the past 2 decades, Valerie’s work has focused on gathering evidence to understand why and how HIV and STIs impact communities differently; and with that understanding developing policies and strategies to prevent, test and treat these early and promote health equity.

6 May 2021 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage: Moderator
6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Clinical Psychologist since 2006.
Psychologist in Low Threshold Methadone Program in Lisbon since 2013.
Working within Research Department of Ares do Pinhal (NGO) since 2014.
Main interests: Health promotion in infectious diseases; harm reduction; psychosocial intervention in dependencies.

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned: PO1/02 Screening, diagnosis and treatment of HCV/HIV during the COVID 19 pandemic: lessons from a Mobile Outreach Program in Lisbon, Portugal

Dr Andrea Ammon, MD, MPH was elected as Director of ECDC on 22 March 2017 and was formally appointed on 16 June 2017. Previously, Dr Ammon was ECDC’s Acting Director from 1 May 2015.

She joined ECDC as the Head of the Surveillance Unit in 2005. The unit was responsible for developing The European Surveillance System (TESSy), implementing a long-term surveillance strategy for the EU, evaluating the Dedicated Surveillance Networks (DSN), performing step-by-step transfer of DSN activities to ECDC, revising the EU case definitions and producing an Annual Epidemiological Report on infectious diseases in the EU.

From April 2011 to April 2015, Andrea Ammon was Deputy to the Director and Head of Unit for Resource Management and Coordination.

Prior to joining the ECDC, Dr Ammon served in several roles at the Robert Koch-Institute, in Berlin, Germany, most recently as Head of Department for Infectious Disease Epidemiology.

5 May 2021 Opening Session: OS/04 Post-2020/COVID-19 and progress towards the SDG targets: Where are we?

Anne Bergenström is a public health professional with over 25 years of professional experience including on social science and epidemiological research on injection drug use, HIV and HCV, as well as having worked as an adviser on HIV prevention and harm reduction. She has a PhD from the Royal Free and University College Medical School and a MSc in Epidemiology from the London School of Hygiene and Medicine, United Kingdom. Since 2000, she mostly worked in the Asia Pacific region, including with UNAIDS, UNICEF, UNODC and the Johns Hopkins University Bloomberg School of Public Health, before joining the EMCDDA in March 2019. She currently works as Scientific analyst on health in the EU4Monitoring Drugs (EU4MD) project.

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): Moderator PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: Moderator

Ben Collins – community organiser; director, ReShape/IHP; board member, EATG; chair, European Testing Week working group; co-founder, European Chemsex Forum; advisory committee, EACS’ WAVE; collaborator, Science Health Education (SHE) Center; HIV+ since 1981; undetectable since 1998; lives in London with his partner of 30 years.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better: PS1/05 European testing week: adaptation of testing services during the COVID-19 pandemic
6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: Moderator

I work at the Luxembourg Health Directorate in the service of infectious diseases since 2013. Before, I worked for 12 years in the main Luxembourg prison where half of my job time was dedicated to infectious diseases issues.
As a background I am a nurse.
I am member of the national HIV, Hepatitis and STI surveillance committee, which is an advisory board to the Minister of Health.
I was a representative for my country in the HIV Think Tank, the ECDC HIV Network and the ECDC Hepatitis Network as well as the Joint Action HA-REACT.
Even if I work meanwhile in different fields on behalf of infectious diseases, my main focus is on HIV and Hepatitis.
During my working life, a big focus was on prevention and education work, test and treat and I had the great opportunity to help to implement very interesting, and today ongoing projects in the prison setting.

6 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB: PS2/02 Combination disease prevention in prisons: a comprehensive programme in Luxembourg

Sophie is current Director of The Sophia Forum, advocating for the rights and dignity of women living with and at risk of HIV. Sophie had been the Co Chair of the UK PrEP IMPACT trial women and other group for the last two years. Sophie works as a sexual health advisor at the Chelsea & Westminster hospital in London UK. Sophie has been living well with HIV for 18 years.

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/07 Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake

Fadi Meroueh is a harm-reduction expert and advocate for health equity and human rights in prisons. Head of the health unit of the Villeneuve-lès-Maguelone prison, in Montpellier, France, in 2018 he was elected president of Health Without Barriers (HWB), the European Federation for Prison Health, which represents prison health professionals, supports evidence-based health-care practices and advocates for prisoners’ rights to health.
A writer and researcher with several peer-reviewed articles to his credit, and 23 years working on prevention and treatment programmes inside prisons in Europe, North Africa and West africa, Meroueh is a member of numerous prison health expert panels including panels convened by the World Health Organization

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): PS4/04 What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs

Dorthe Raben is Director of Research Coordination at CHIP, Rigshospitalet, University of Copenhagen. Under the public health activities at CHIP, she has been managing the Secretariat for the EuroTEST (formerly HIV in Europe) initiative since 2009, Coordinator for the OptTEST EU co-financed project (2014-2017) and the INTEGRATE Joint Action (2017-2021).

5 May 2021 Opening Session: OS/01 Conference objectives and overview

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: The INTEGRATE Story & INTEGRATE at HepHIV

Jens Lundgren – professor of infectious diseases at Dept. of Clinical Medicine, Faculty of Health Sciences at the University of Copenhagen, and chief physician at Dept. of Infectious Diseases, Rigshospitalet. Primary research focus are clinical and public health aspects of the HIV infection itself, and its infectious and non-infectious associated morbidities. In recent years, focus expanded to include respiratory infections (e.g. influenza and recently SARS-CoV-2), and infections in patients with other types of immune dysfunction (incl transplantation, oncology, hematology, and treated patients with autoimmune disease). Appointed as the global leader of ACTIV-3, consisting of 1500 researchers, which over the next few years will uncover the importance of the antibodies that the body forms after infection with coronavirus in a trial with over 10,000 patients.
Director of CHIP, www.chip.dk
Heads PERSIMUNE, www.persimuine.dk
https://publons.com/researcher/3196617/jens-lundgren/

Jens Lundgren
7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Panellist

Doctor of biomedical science (2006), Director of Kaunas branch, Republican Centre for Addictive Disorders, Lithuania, more than 20 years’ experience in HIV/AIDS and addiction field, more than 20 books with co-authors, majority of them methodological recommendations for teachers, public health care specialists, police, and prison officers.

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/06 Expanding integrated HCV/HIV testing to alcohol dependent clients attending treatment centres for drug and alcohol dependency in Lithuania

Sophie Strachan¹Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/07 Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake

Raluca Teodorescu, social worker with ARAS – The Romanian Association Against AIDS. I have been working with this association since 2007 and I have been involved in a number of projects regarding outreach work, harm reduction and methadone treatment both in the field and in our dedicated centers. I also do HIV, hepatitis C an B rapid testing and counseling. I work with injectable drug users, sex workers, people leaving with HIV, MSM and other at risk individuals.

7 May 2021 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD: AS2/01 Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategy

António Lacerda Sales is the Assistant State Secretary for Health of Portugal. Doctor, specialized in Orthopedic surgery, he was previously a MP (Member of Parliament) between 2015 and 2019, before joining the Portuguese Government in October 2019.

5 May 2021 Opening Session: OS/02 Welcome message from the Portuguese Minister of Health

Doctoral Candidate at the Department of Health Policy and Management, School of Public Health, University of North Carolina at Chapel Hill, USA (Health Services Research);
Especialista em Saúde Pública (1995);
Master of Science in Public Health Medicine, London School of Hygiene and Tropical Medicine, University of London (1992);
Licenciado em Medicina pela Faculdade de Medicina da Universidade de Lisboa (1987).

5 May 2021 Opening Session: OS/06 Country Spotlight: Portugal’s progress in reaching the global targets and interventions for integration of testing

Dr Winter was appointed Consultant in Sexual Health and HIV in Glasgow, UK in 1999 after completing a PhD in Infection at Birmingham University. His clinical interests are in digital health transformation, HIV care and STI diagnostic testing. He is a member of the European IUSTI Guidelines Group (leading the 2017 Hepatitis guideline update), UK Country Representative for IUSTI Europe and chairs IUSTI Europe’s communication group.

7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Panellist

Member of the Portuguese National Parliament, Vice-President of the Social Democratic Party Parliamentary Board, National Spokesperson for Health of the Social Democratic Party, Medical Doctor trained in infectious diseases and Head of Public Health at Católica University of Portugal.
Founder and President of ‘UNITE – Global Parliamentarians Network to End HIV/AIDS, Viral Hepatitis and other Infectious Diseases’, a global platform of current and former policy makers committed to ending these public health threats by 2030 in accordance with the UN SDG’s.
Vice President of the ‘Parliamentary Network on The World Bank & International Monetary Fund’.
Global Ambassador of the ‘G20 Health & Development Partnership’ aimed at advising and advocating G20 countries on health policies aligned with the UN Sustainable Development Goals.
Guest Lecturer at NOVA Medical School.
Awarded by ‘The Economist Intelligence Unit’ as a ‘HCV Change Maker’ (2016).

5 May 2021 Opening Session: HepHIV2021 Lisbon & Virtual Conference Co-chair. OS/00 Welcome to the HepHIV 2021 Lisbon & Virtual Conference

7 May 2021 Closing Session: Integrating disease areas and settings: Panellist

Anastasia Pharris is an Expert in HIV, Coronavirus and Influenza at the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden. She is a nurse with Masters degrees in public health and community health nursing and a PhD in public health. Since 1997 she has worked on clinical and public health aspects in the USA, Uganda, Zambia, Vietnam, Sweden and, now, at European-level. At ECDC she is responsible for HIV surveillance within the countries of the European Union and scientific advice activities in the area of COVID-19.

7 May 2021 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies: Moderator

I was graduated in Medicine from the Autonomous University of Barcelona in 2009. I have completed the MIR specialty in Internal Medicine at the Vall d’Hebron University Hospital, Barcelona. I finished my training in 2015 with a special focus on hepatobiliary pathology and specifically on viral hepatitis, essentially medical and viral liver diseases, is the key topic of HCV eradication strategies.

Coordinator of the Cardiopulmonary Resuscitation commission of the ED of the Hospital Vall d’Hebron and intensely linked to medical training, participant in the Emergency Simulation Group and associate professor at the Master of Critical and Emergency Medicine of the Hospital Clinic of Barcelona.

Author of more than 13 original articles in journals of high scientific impact, as well as collaborator of multiple clinical trials related to emergency care and viral hepatitis, highlighting the universal HCV screening program in emergencies.

Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings: PO4/02 Towards a hepatitis C-free hospital: results after one year of hepatitis C virus screening in a tertiary hospital emergency department in a high-income country

Eugenia Saraiva is a Clinical Psychologist with degree in Clinical/Counseling Psychology, specialized in Sexuality Studies and postgraduate in Infectious Diseases. Since 1990 has worked in HIV/AIDS and other STI area and for the past 12 years has been the President of Portuguese League Against Aids.

Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO5/03 Reaching 95-95-95: 3 years of the Portuguese League Against AIDS performing screening tests and promoting therapeutical compliance

Nadia Gasbarrini is Programme Manager at Villa Maraini Foundation, coordinating international projects and activities on substance abuse prevention, treatment and care. She has been working in this field since more than 20 years; before the actual position, she worked with UNODC (United Nations Office on Drugs and Crime) in Moscow as Coordinator of a UNODC/WHO joint project on substance abuse prevention and with OSCE (Organization for Security and Co-operation in Europe) in Bosnia-Herzegovina as Coordinator of youth projects on capacity building and social reintegration. She is author/co-author of several publications on harm reduction, peer education, drug abuse-related programmes and policies. As consultant of the IFRC Partnership on Substance abuse, she has organized more than 40 training and seminars on harm reduction and humanitarian drug policy for Red Cross/Red Crescent Societies and NGOs, and has participated in various field missions for project monitoring and evaluation.

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Nikoloz Chkhartishvili graduated from Tbilisi Medical Institute with MD degree, he obtained MS degree in epidemiology from the State University of New York (SUNY) at Albany and PhD degree in infectious diseases from Tbilisi State University (TSU).

Currently Dr. Chkhartishvili holds the position of Deputy Director for Research at the Infectious Diseases, AIDS and Clinical Immunology Research Center in Tbilisi, Georgia, which is country’s leading institution in the field of HIV, viral hepatitis and other infectious diseases. He has been leading national HIV treatment and care program since 2008.

Dr. Chkhartishvili has over 15 years of experience in HIV, HCV and other infectious diseases research. He has published extensively in peer-reviewed literature and also co-authored several national and international guidelines

7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Panellist

Paul Sommerfeld is Chair of TB Europe Coalition, active across Europe and Central Asia since 2009. Using his early career skills in facilitation and organisation development, he is also a lead trainer for TBEC, facilitating numerous TB advocacy workshops across the region.

He is also Executive Trustee of TB Alert, a UK-based NGO with programmes in Africa, India and the UK.

Paul has been involved in global health action for over 30 years – first leprosy, then TB, and also influenza; with a focus on advocacy and community engagement.

He has held a series of UK public appointments – as Chair of a National Health Service operational Trust responsible for mental health services in a large part of West London, and as a lay member in organisations responsible for the professional regulation of judges, barristers, osteopaths, and pharmacists.

7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Panellist

Cary James is the chief executive of the World Hepatitis Alliance (WHA) – a global network of community-led organisations in 100 countries. WHA advocates at global, national and regional levels to keep hepatitis on top of the health agenda. WHA raises the voices of the people and communities affected by viral hepatitis, calling for urgent action to see the elimination of viral hepatitis by 2030.

He began his career in the grassroots HIV movement in London. He went on to become Head of Health Improvement Programmes at the Terrence Higgins Trust and HIV Prevention England.

He is the former chair of European Testing Week and advisory board member of INTEGRATE. He is a previous faculty member of the European AIDS Clinical Society’s online course on HIV management.

He is currently the civil society representative for the global north on the steering committee of UHC2030.

He holds a Masters degree in health and social marketing.

6 May 2021 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage: Moderator
7 May 2021 Closing Session: Integrating disease areas and settings: Panellist

Jennifer Taylor, MPH MFPH is a senior Public Health Specialty Registrar currently working with SH:24, a Community Interest Company providing free online sexual health services across the UK. She lives and works in London, England.

6 May 2021 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage: AS1/02 An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing policy

Yazdan Yazdanpanah is Director of the French ANRS emerging infectious diseases Agency that fund and coordinates research on HIV, Hepatitis, STIs, Tuberculosis and emerging and re-emerging infections, he is Director of Aviesan Institute of Immunology, Inflammation, Infectiology, and Microbiology which gathers the main stakeholders of this thematic in France in the frame of Aviesan (French National Alliance for Life Sciences and Health). He is the head of the Infectious Disease department at Bichat Hospital, and he is Professor of Medicine at Paris Diderot University, France. He is the Chair of « The European & Developing Countries Clinical Trials Partnership » (EDCTP) board and the Vice-Chair of the « Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) board. Master of Science degree in epidemiology from the Harvard School of Public Health and a Ph.D degree in public health from the Bordeaux School of Public Health.

7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Panellist

European AIDS Treatment Group (EATG): “Nikos Dedes is past Chair of the Board of Directors at EATG, a voluntary organisation with more than 90 members across 30 different European countries, founded in 1991. He is the founder of the NGO ’Synthesis’, which aims to increase awareness, prevent and promote scientific research about HIV/AIDS in Greece. He is also Co-Chair of the HIV/AIDS Civil Society Forum.”

7 May 2021 CLOSING SESSION: Integrating disease areas and settings: Panellist

European Commission, DG Sante: “Ana Burgos Gutierrez is a EU4health Programme Officer dealing with actions on cross-border health treats. Previously working in the Commission’s COVID-19 Clearing House and medical devices. Previous experience in the national public administration in the fields of medicinal products, medical devices and food safety.”

6 May 2021 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action: Panellist

Linda Montanari, health sociologist, is a principal scientist at European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), where she arrived in 2000. Her work has been focusing on health and social problems and responses to the drug problem in the European countries, including on issues such as social exclusion, prison and more recently gender and drugs. She has been implementing the treatment demand indicator for more than 15 years, being responsible for the revision of the data collection protocol. Currently she is coordinating the drugs and prison monitoring, with the objective to improve the evidence on this issue in the European countries. The work aims at improving availability and comparability of the information on the drug problem among people in prison and on the drug related interventions in prison across EU countries. Standard monitoring tools for collecting information on drugs and prison, developed with the support of a European group of prison experts, include a European Questionnaire for conducting prison and drugs survey and a draft survey on prison interventions.

7 May 2021 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC): Moderator

Cristina Agustí

Olga Anagnostou

Magdalena Ankiersztejn-Bartczak

Marios Atzemis

Álvaro Ávila

Anamika Basu

Nikolina Bogdanić

Jordi Casabona i Barbarà

Andrii Chernyshev

Paula Costa

Sara Croxford

Maka Danelia

Gerard de Vries

Eva Emanuel

Claudia Estcourt

Laura Fernàndez-López

Cinta Folch

Megi Gogishvili

Ilias Gountas

Robert Hejzak

Carlo Kantwerk

Michel Kazatchkine

Hans Kluge

John (Jack) Lambert

H. Clifford Lane

Jeffrey Lazarus

Mihai Lixandru

Otilia Mårdh

Valentina Mascia

Raimonda Matulionyte

Sara Mazzilli

Cristiana Merendeiro

Viktor Mravčík

Chattiya Nitpolprasert

Anne-Sophie Petit

Manuel Reiriz Rojas

Rafaela Rigoni

Mar Riveiro-Barciela

Jürgen Rockstroh

Ana Luísa Rosa

John F. Ryan

Ana-Maria Schweitzer

Svetlana Semikova

Thomas Seyler

Sam Shirley-Beavan

Elizabeth Smout

Victor Stanilevskiy

Hannah Taylor

Jorge Valencia

Maria Vasileioy

Koenraad Vermey

Nicole Seguy

Lella Cosmaro

Walter Cullen

Teymur Noori

Luís Mendão

Daniel Simões

Eberhard Schatz

Ann Sullivan

Valérie Delpech

Filipa Barata

Andrea Ammon

Anne Bergenström

Ben Collins

Patrick Hoffmann

Sophie Strachan

Fadi Meroueh

Dorthe Raben

Jens Lundgren

Loreta Stoniene

Raluca Teodorescu

António Lacerda Sales

Rui Portugal

Andrew Winter

Ricardo Baptista Leite

Anastasia Pharris

Jordi Llaneras

Maria Eugénia Saraiva

Nadia Gasbarrini

Nikoloz Chkhartishvili